X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (705) 705
acenocoumarol - therapeutic use (485) 485
female (439) 439
male (427) 427
anticoagulants - therapeutic use (369) 369
middle aged (369) 369
aged (312) 312
adult (256) 256
acenocoumarol (235) 235
warfarin (208) 208
index medicus (177) 177
acenocoumarol - administration & dosage (157) 157
acenocoumarol - adverse effects (157) 157
anticoagulants - adverse effects (153) 153
anticoagulants - administration & dosage (147) 147
international normalized ratio (143) 143
aged, 80 and over (134) 134
hematology (134) 134
anticoagulants (131) 131
administration, oral (126) 126
peripheral vascular disease (101) 101
pharmacology & pharmacy (88) 88
treatment outcome (86) 86
hemorrhage - chemically induced (85) 85
heparin - therapeutic use (79) 79
risk factors (79) 79
warfarin - therapeutic use (78) 78
therapy (75) 75
vitamin k - antagonists & inhibitors (69) 69
drug interactions (67) 67
time factors (67) 67
thromboembolism - prevention & control (63) 63
cyp2c9 (61) 61
medicine, general & internal (61) 61
phenprocoumon (60) 60
prospective studies (60) 60
blood coagulation - drug effects (59) 59
pharmacogenetics (59) 59
follow-up studies (58) 58
adolescent (55) 55
risk (55) 55
acenocoumarol - pharmacology (54) 54
atrial fibrillation - drug therapy (54) 54
genotype (54) 54
retrospective studies (54) 54
dose-response relationship, drug (52) 52
drug therapy, combination (51) 51
thromboembolism (51) 51
vkorc1 (51) 51
prothrombin time (47) 47
venous thrombosis - drug therapy (44) 44
algorithms (43) 43
anticoagulants - pharmacology (43) 43
anticoagulation (42) 42
aryl hydrocarbon hydroxylases - genetics (42) 42
cytochrome p-450 cyp2c9 (42) 42
management (42) 42
thrombosis - drug therapy (42) 42
warfarin - administration & dosage (42) 42
oral anticoagulants (40) 40
phenprocoumon - therapeutic use (40) 40
atrial fibrillation (39) 39
atrial-fibrillation (39) 39
oral anticoagulant-therapy (39) 39
recurrence (39) 39
thrombophlebitis - drug therapy (39) 39
cohort studies (38) 38
heparin, low-molecular-weight - therapeutic use (38) 38
phenprocoumon - administration & dosage (38) 38
thrombosis (38) 38
thrombosis - prevention & control (38) 38
heart valve prosthesis (36) 36
warfarin - adverse effects (35) 35
drug therapy (34) 34
mixed function oxygenases - genetics (34) 34
thromboembolism - drug therapy (34) 34
hemorrhage (33) 33
vitamin k epoxide reductases (33) 33
stroke (32) 32
cardiac & cardiovascular systems (31) 31
heparin - administration & dosage (31) 31
postoperative complications - prevention & control (31) 31
anticoagulants - pharmacokinetics (30) 30
atrial fibrillation - complications (30) 30
fibrinolytic agents - therapeutic use (30) 30
oral anticoagulation (30) 30
pregnancy (30) 30
pulmonary embolism - drug therapy (30) 30
venous thromboembolism (30) 30
aspirin - therapeutic use (29) 29
blood coagulation tests (29) 29
prevention (29) 29
analysis (28) 28
bleeding complications (28) 28
clinical trials as topic (28) 28
phenprocoumon - adverse effects (28) 28
young adult (28) 28
acenocoumarol - pharmacokinetics (27) 27
hemorrhage - epidemiology (26) 26
medicine & public health (26) 26
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (531) 531
Spanish (63) 63
French (54) 54
German (32) 32
Hungarian (25) 25
Dutch (15) 15
Polish (15) 15
Russian (14) 14
Italian (6) 6
Bulgarian (3) 3
Romanian (3) 3
Chinese (1) 1
Japanese (1) 1
Norwegian (1) 1
Portuguese (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 12/2010, Volume 363, Issue 26, pp. 2499 - 2510
In this clinical trial, rivaroxaban, an oral factor Xa inhibitor, was effective in the initial and continued treatment of symptomatic venous thromboembolism;... 
MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | THERAPY | DISEASE | PREVENTION | DEEP-VEIN THROMBOSIS | IDRAPARINUX | Thiophenes - therapeutic use | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Warfarin - adverse effects | Male | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - drug therapy | Warfarin - therapeutic use | Rivaroxaban | Vitamin K - antagonists & inhibitors | Injections, Subcutaneous | Female | Morpholines - adverse effects | Morpholines - therapeutic use | Acute Disease | Double-Blind Method | Venous Thrombosis - drug therapy | Administration, Oral | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Acenocoumarol - adverse effects | Intention to Treat Analysis | Pulmonary Embolism - drug therapy | Acenocoumarol - therapeutic use | Aged | Hemorrhage - chemically induced | Anticoagulants (Medicine) | Thromboembolism | Drug therapy | Health aspects | Risk factors | Anticoagulants | Bone surgery | Veins & arteries | Venous Thrombosis | Factor Xa | Hemorrhage | Life Sciences | Venous Thromboembolism | Thiophenes | Acenocoumarol | Vitamin K | Warfarin | Enoxaparin | Morpholines | Human health and pathology | Pulmonary Embolism | MEDICIN OCH HÄLSOVETENSKAP | Oral | MEDICAL AND HEALTH SCIENCES | Administration | chemically induced | drug therapy | Subcutaneous | antagonists & inhibitors | Injections | adverse effects | therapeutic use
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2007, Volume 357, Issue 3, pp. 217 - 227
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2003, Volume 349, Issue 2, pp. 146 - 153
Journal Article
Journal Article
World Neurosurgery, ISSN 1878-8750, 2016, Volume 95, pp. 143 - 147
Journal Article
Journal of Clinical Epidemiology, ISSN 0895-4356, 06/2017, Volume 86, pp. 75 - 83
Nonvalvular atrial fibrillation (NVAF) is a risk factor for ischemic stroke and systemic embolism. New oral anticoagulants are currently available. The... 
Cost–utility | Novel anticoagulants | Cost-effectiveness | Atrial fibrillation | Apixaban | Acenocoumarol | UNITED-KINGDOM | STROKE PREVENTION | RIVAROXABAN | PHARMACODYNAMICS | PREVALENCE | Cost-utility | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | DABIGATRAN | PHARMACOKINETICS | WARFARIN | ORAL ANTICOAGULANTS | HEALTH CARE SCIENCES & SERVICES | ISCHEMIC-STROKE | Cost-Benefit Analysis - economics | Epidemiologic Studies | Pyrazoles - therapeutic use | Stroke - prevention & control | Humans | Anticoagulants - economics | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Male | Risk | Cost-Benefit Analysis - statistics & numerical data | Pyrazoles - economics | Latin America | Factor Xa Inhibitors - therapeutic use | Factor Xa Inhibitors - economics | Female | Acenocoumarol - therapeutic use | Aged | Pyridones - therapeutic use | Chile | Pyridones - economics | Acenocoumarol - economics | Stroke (Disease) | Markov processes | Anticoagulants (Medicine) | Epidemiology | Risk factors | Embolism | Low income groups | Cardiac arrhythmia | Embolisms | Markov chains | Service life assessment | Hemorrhage | Prevention | Utilities | Fibrillation | Ischemia | Drug dosages | Public health | Age | Anticoagulants | Stroke | Sensitivity analysis | Mortality | Norms | Patients | Studies | Clinical medicine | Cost analysis
Journal Article